Literature DB >> 1121004

Studies on cyclophosphamide metabolites and their related compounds. 2. Preparation of an active species of cyclophosphamide and related compounds.

A Takamizawa, S Matsumoto, T Iwata, Y Tochino, K Katagiri, K Yamaguchi.   

Abstract

A synthetic study was made on the active metabolite of cyclophosphamide. Ozonolysis of O-(3 butenyl)-N,N-bis(2-chloroethyl)phosphorodiamidate, prepared by reaction of POC13 with 3-buten-1-ol followed by treatment with N,N-bis(2-chloroethyl)amine (nor mustard) and NH3, afforded 2-[bis(2-chloroethyl)amino]-4-hydroperoxytetrahydro-2H-1, 3,2-oxazaphosphorine 2-oxide (4-hydroperoxycyclophosphamide). Deoxygenation of 4-hydroperoxycyclophosphamide by triphenylphosphine yielded 4-hydroxycyclophosphamide in a pure crystalline state. These products exhibited high cytostatic activity in both in vitro and in vivo experiments. The results give confirmatory evidence for the hypothesis that C4-hydroxylation on the 1,3,2-oxazaphosphorinane ring of cyclophosphamide is necessary for its activation.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1121004     DOI: 10.1021/jm00238a011

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  12 in total

1.  Proton magnetic resonance studies of the decomposition of 4-hydroxycyclophosphamide, a microsomal metabolite of cyclophosphamide.

Authors:  E J Valente; K K Chan; K L Servis
Journal:  Pharm Res       Date:  1984-03       Impact factor: 4.200

2.  Inhibitors of apoptosis protect the ovarian reserve from cyclophosphamide.

Authors:  Yi Luan; Maxwell E Edmonds; Teresa K Woodruff; So-Youn Kim
Journal:  J Endocrinol       Date:  2019-02-01       Impact factor: 4.286

3.  [On the binding of cyclophosphamide and cyclophosphamide-metabolites to serum-albumin (author's transl)].

Authors:  G Voelcker; H P Giera; L Jäger; H J Hohorst
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1978-05-31

4.  YIGSR, a synthetic laminin peptide, inhibits the enhancement by cyclophosphamide of experimental lung metastasis of human fibrosarcoma cells.

Authors:  Y Iwamoto; Y Fujita; Y Sugioka
Journal:  Clin Exp Metastasis       Date:  1992-05       Impact factor: 5.150

5.  In vitro synergism of 4-hydroperoxycyclophosphamide and cisplatin: relevance for bone marrow purging.

Authors:  R H Peters; C S Brandon; L A Avila; O M Colvin; R K Stuart
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  Inhibition of carboxyethylphosphoramide mustard formation from 4-hydroxycyclophosphamide by carmustine.

Authors:  S Ren; J T Slatterly
Journal:  AAPS PharmSci       Date:  1999

7.  Effect of liver failure on the pharmacokinetics of cyclophosphamide.

Authors:  F D Juma
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

8.  Autologous bone marrow transplantation for acute leukemia using transplant chemopurified with metabolite of oxazaphosphorines (ASTA Z 7557, INN mafosfamide). First clinical results.

Authors:  P Hervé; J Y Cahn; E Plouvier; M Flesch; E Tamayo; R Leconte des Floris; A Peters
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

9.  Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites.

Authors:  F D Juma; H J Rogers; J R Trounce
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

10.  Preclinical pharmacokinetics and stability of isophosphoramide mustard.

Authors:  J J Zheng; K K Chan; F Muggia
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.